LGD1069: An antagonist to the X retinoid receptor (rexinoid);LGD1069: Un antagoniste du recepteur X aux retinoides (rexinoide)

Bulletin du Cancer

Volumn 87, Issue 3, 2000, Pages 235-238

  Lansiaux, Amélie ^a   Formstecher, Pierre ^b   Bailly, Christian ^a  

^a CENTRE OSCAR LAMBRET   (France)

^b INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

3,5 DI TERT BUTYL 4' CHALCONECARBOXYLIC ACID; 6 [3 (1 ADAMANTYL) 4 HYDROXYPHENYL] 2 NAPHTHOIC ACID; ALITRETINOIN; BEXAROTENE; ISOTRETINOIN; LGD 100268; RETINOIC ACID; RETINOIC ACID DERIVATIVE; RETINOID X RECEPTOR; TAMIBAROTENE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; RETINOIC ACID RECEPTOR; TETRALIN DERIVATIVE; TRANSCRIPTION FACTOR;

AREA UNDER THE CURVE; CANCER; DRUG ANTAGONISM; DRUG EFFECT; DRUG MECHANISM; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG STRUCTURE; HUMAN; NONHUMAN; RECEPTOR AFFINITY; REVIEW; ANIMAL; ARTICLE; CELL CULTURE; CHEMISTRY; CLINICAL TRIAL; DIMERIZATION; DRUG ERUPTION; DRUG SCREENING; LUNG TUMOR; MOUSE; RAT; SKIN TUMOR; STRUCTURE ACTIVITY RELATION; T CELL LYMPHOMA; TRANSACTIVATION;

ANIMALS; ANTICARCINOGENIC AGENTS; CELLS, CULTURED; CLINICAL TRIALS; DIMERIZATION; DRUG ERUPTIONS; DRUG EVALUATION; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; LUNG NEOPLASMS; LYMPHOMA, T-CELL; MICE; RATS; RECEPTORS, RETINOIC ACID; RETINOID X RECEPTORS; SKIN NEOPLASMS; STRUCTURE-ACTIVITY RELATIONSHIP; TETRAHYDRONAPHTHALENES; TRANS-ACTIVATION (GENETICS); TRANSCRIPTION FACTORS;

EID: 0034152249     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (27)

1. Warrell RP, de The H, Wang ZY, Degos L. Acute promyelocytic leukemia. N Engl J Med 1993 ; 329 : 177-89.
2. Chambon P. The retinoid signaling pathway: molecular and genetic analyses. Semin Cell Biol 1994 ; 5 : 115-25.
3. Chambon P. A decade of molecular biology of retinoic acid receptors. FASEB J 1996 ; 10 : 940-54.
4. Mangelsdorf DJ, Ong ES, Dyck JA, Evans RM. Nuclear receptor that identifies a novel retinoic acid response pathway. Nature 1990 ; 345 : 224-9.
5. Keller H, Dreyer C, Medin J, Mahfoudi A, Ozato K, Wahli W. Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator-activated receptor-retinoid X receptor heterodimers. Proc Natl Acad Sci USA 1993 ; 90 : 2160-4.
6. Zhang XK, Hoffmann B, Tran PB, Graupner G, Pfahl M. Retinoid X receptor is an auxiliary protein for thyroid hormone and retinoic acid receptors. Nature 1992 ; 355 : 441-6.
7. Kliewer SA, Umesono K, Mangelsdorf DJ, Evans RM. Retinoid X receptor interacts with nuclear receptors in retinoic acid, thyroid hormone and vitamin D3 signalling. Nature 1992 ; 355 : 446-9.
8. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, et al. The nuclear receptor superfamily: the second decade. Cell 1995 ; 83 : 835-9.
9. Kitamura K, Kiyoi H, Yoshida H, Tobita T, Takeshita A, Ohno R, et al. New retinoids and arsenic compounds for the treatment of refractory acute promyelocytic leukemia: clinical and basic studies for the next generation. Cancer Chemother Pharmacol 1997 ; 40 : S36-41.
10. Gottardis MM, Bischoff ED, Shirley MA, Wagoner MA, Lamph WW, Heyman RA. Chemoprevention of mammary carcinoma by LGD1069 (Targretin): an RXR-selective ligand. Cancer Res 1996 ; 56 : 5566-70.
11. Boehm MF, Zhang L, Badea BA, White SK, Mais DE, Berger E, et al. Synthesis and structure-activity relationships of novel retinoid X receptor-selective retinoids. J Med Chem 1994 ; 37 : 2930-41.
12. Boehm MF, McClurg MR, Pathirana C, Mangelsdorf D, White SK, Hebert J, et al. Synthesis of high specific activity [3H]-9-cis-retinoic acid and its application for identifying retinoids with unusual binding properties. J Med Chem 1994 ; 37 : 408-14.
13. Boehm MF, Zhang L, Zhi L, McClurg MR, Berger E, Wagoner M, et al. Design and synthesis of potent retinoid X receptor selective ligands that induce apoptosis in leukemia cells. J Med Chem 1995 ; 38 : 3146-55.
14. Sun SY, Yue P, Dawson MI, Shroot B, Michel S, Lamph WW, et al. Differential effects of synthetic nuclear retinoid receptor-selective retinoids on the growth of human non-small cell lung carcinoma cells. Cancer Res 1997 ; 57 : 4931-9.
15. Mukherjee R, Davies PJ, Crombie DL, Bischoff ED, Cesario RM, Jow L, et al. Sensitization of diabetic and obese mice to insulin by rerinoid X receptor agonists. Nature 1997 ; 386 : 407-10.
16. Vu-Dac N, Schoonjans K, Kosykh V, Dallongeville J, Heyman RA, Staels B, et al. Retinoids increase human apolipoprotein A-11 expression through activation of the retinoid X receptor but not the retinoic acid receptor. Mol Cell Biol 1996 ; 16 : 3350-60.
17. Vu-Dac N, Gervois P, Torra IP, Fruchart JC, Kosykh V, Kooistra T, et al. Retinoids increase human apo C-III expression at the transcriptional level via the retinoid X receptor: contribution to the hypertriglyceridemic action of retinoids. J Clin Invest 1998 ; 102 : 625-32.
18. Neele DM, de Wit EC, Princen HM. Inhibition of apolipoprotein(a) synthesis in cynomolgus monkey hepatocytes by retinoids via involvement of the retinoic acid receptor. Biochem Pharmacol 1999 ; 58 : 263-71.
19. Rizvi NA, Marshall JL, Dahut W, Ness E, Truglia JA, Loewen G, et al. A phase I study of LGD1069 in adults with advanced cancer. Clin Cancer Res 1999 ; 5 : 1658-64.
20. Howell SR, Shirley MA. Effects of retinoid treatment of rats on hepatic microsomal metabolism and cytochromes P450 : correlation between retinoic acid receptor/retinoid x receptor selectivity and effects on metabolic enzymes. Drug Metab Dispos 1998 ; 26 : 234-9.
21. Bischoff ED, Gottardis MM, Moon TE, Heyman RA, Lamph WW. Beyond tamoxifen: the retinoid X receptor-selective ligand LGD1069 (Targretin) causes complete regression of mammary carcinoma. Cancer Res 1998 ; 58 : 479-84.
22. Bischoff ED, Heyman RA, Lamph WW. Tamoxifene resistance : the RXR-selective ligand LGD1069 causes complete regression of ramoxifen resistant mammary carcinoma. Proc Am Ass Cancer Res 1999 ; 40 : 2054.
23. Fitzgerald P, Teng M, Chandraratna RA, Heyman RA, Allegretto EA. Retinoic acid receptor alpha expression correlates with retinoid-induced growth inhibition of human breast cancer cells regardless of estrogen receptor status. Cancer Res 1997 ; 57 : 2642-50.
24. Darro F, Cahen P, Vianna A, Decaestecker C, Nogaret JM, Leblond B, et al. Growth inhibition of human in vitro and mouse in vitro and in vivo mammary tumor models by retinoids in comparison with ramoxifen and the RU-486 anti-progestagen. Breast Cancer Res Treat 1998 ; 51 : 39-55.
25. Miller VA, Benedetti FM, Rigas JR, Verret AL, Pfister DG, Straus D, et al. Initial clinical trial of a selective retinoid X receptor ligand, LGD1069. J Clin Oncol 1997 ; 15 : 790-5.
26. Papadimitrakopoulou V, Khuri FR, Lippman SM, Shin DM, Ginsberg L, Glisson BS, et al. Phase I/II evaluation of Targretin (LGD1069), a novel RXR-specific retinoid, in patients with recurrent squamous cell carcinoma of the head and neck. Proc Am Soc Clin Oncol 1998 ; 17 : 1512.
27. Rigas JR, Maurer LH, Meyer LP, Hammond SM, Crisp MR, Parker BA, et al. Targretin™, a selective retinoid X receptor ligand (LGD1069), vinorelbine and cisplatin for the treatment of non-small cell lung cancer (NSCLC) : a phase I/II trial. Proc Am Soc Clin Oncol 1997 ; 16 : 1724.